Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

14.91
-0.4100-2.68%
Post-market: 15.100.1900+1.27%19:25 EDT
Volume:1.13M
Turnover:16.90M
Market Cap:1.32B
PE:-5.37
High:15.51
Open:15.51
Low:14.81
Close:15.32
Loading ...

Travere Therapeutics Inc. Announces Amendments to Equity Incentive Plan, Approved by Stockholders

Reuters
·
17 May

Travere Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since September 2023 -- Data Talk

Dow Jones
·
16 May

Scotiabank Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
16 May

Travere Therapeutics' FDA Application Accepted for Filspari in Rare Kidney Disease

MT Newswires Live
·
16 May

Travere Therapeutics' FILSPARI sNDA for FSGS Treatment Accepted by FDA; PDUFA Target Date Set for January 2026

Reuters
·
16 May

BRIEF-Travere Therapeutics Announces FDA Acceptance Of SNDA For FILSPARI® (Sparsentan) In FSGS

Reuters
·
16 May

Travere Therapeutics Announces FDA Acceptance of Snda for Filspari® (Sparsentan) in Fsgs

THOMSON REUTERS
·
16 May

Travere Therapeutics Inc - Filspari Could Be First FDA-Approved Treatment for Fsgs

THOMSON REUTERS
·
16 May

Travere Therapeutics Inc - Pdufa Target Action Date Set for January 13, 2026

THOMSON REUTERS
·
16 May

Travere Therapeutics Announces Inducement Equity Grants for New Employees Under Nasdaq Rule 5635(c)(4)

Reuters
·
13 May

TD Cowen Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
08 May

CFO Christopher R. Cline Reports Disposal of Common Shares in Travere Therapeutics Inc

Reuters
·
06 May

Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report

Simply Wall St.
·
04 May

Piper Sandler Sticks to Their Hold Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
02 May

Travere Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
02 May

Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates

Zacks
·
02 May

Earnings Flash (TVTX) Travere Therapeutics Q1 Adjusted Loss Per Share $0.19 vs. FactSet Est Loss $0.36

MT Newswires Live
·
02 May

BRIEF-Travere Therapeutics Q1 EPS USD -0.47 Vs. IBES Estimate USD -0.54

Reuters
·
02 May

Travere Therapeutics Q1 EPS USD -0.47 VS. Ibes Estimate USD -0.54

THOMSON REUTERS
·
02 May

Press Release: Travere Therapeutics Reports First Quarter 2025 Financial Results

Dow Jones
·
02 May